Lab-on-Skin: A wearable medical device for improved clinical trial monitoring

Project Information

Lab-on-Skin

Grant agreement ID: 817113

DOI

10.3030/817113

Project closed

EC signature date 30 May 2018

Start date 1 May 2018

End date 31 October 2018

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

XSENSIO SA
Switzerland

Periodic Reporting for period 1 - Lab-on-Skin (Lab-on-Skin: A wearable medical device for improved clinical trial monitoring)

Reporting period: 2018-05-01 to 2018-10-31

Summary of the context and overall objectives of the project

The goal of the feasibility study was to define the most promising application in the medical space that would open up a large spectrum of opportunities for the future. Sweat offers a very compelling non-invasive alternative to blood testing: it is continuously produced by the body, available in a non-intrusive way for testing, and more importantly, it is biomarker-rich. Furthermore, sweat is routinely used by the medical community for the detection of cystic fibrosis, drug abuse and athletic performance optimization. The pharma market has shown strong interest in Xsensio’s solution, and a collaboration is already in place with one of the big pharma companies to customize the Lab-on-SkinTM platform for specific medical applications.
The Xsensio Lab-on-SkinTM sensing platform is indeed highly versatile and can be applied to a wide range of applications, in sports & wellness and also in the medical field. It relies on unique, highly-innovative nanotechnology. Compared to conventional sensors used by competitors in the sweat sensing space, our sensors are (a) in the nanometer scale rather than millimeter or centimeter scale, making multi-parametric sensing in wearable format possible, (b) are fundamentally more sensitive, capable of reaching concentration levels at least 10'000x smaller, making our technology able to target a much wider spectrum of sweat components and detect very small changes early on and (c) require only a few nanoliters of sweat to activate the sensor.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

The SME Phase 1 grant enabled Xsensio to conduct a fruitful feasibility analysis into the medical space, centered around two parts: (1) a screening of all potential medical applications which could benefit from the Lab-on-SkinTM sensing platform, ranked according to various criteria, leading to the selection of 6 most promising medical applications. And (2) an analysis of the regulatory landscape to identify the regulatory pathway to a B2B commercialization in the EU and the US.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The SMEi Phase 1 allowed the company to identify new opportunities for growth in the medical space, outline a sound regulatory pathway and strengthen its B2B commercialization strategy.

xsensio-chip.jpg